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Rapport de synthèse 
Le traitement des leucémies aiguës chez l'enfant représente un des succès de la médecine 
moderne avec des taux de guérison avoisinant les 80% ce qui implique la nécessité de 
suivre les effets secondaires à long terme des traitements chez cette population de 
patients. Récemment plusieurs études internationales ont relevé une prévalence plus 
importante de surpoids et d'obésité chez les enfants traités pour une leucémie aiguë. 
L'origine de ce processus reste incertaine : aux effets secondaires bien connus et décrits 
des traitements (stéroïdes et radiothérapie) semblent s'ajouter des facteurs génétiques, 
familiaux (age, BMI au diagnostic, BMI parents et fratrie), environnementaux. 
L'objectif de ce travail est d'estimer la prévalence et les facteurs de risque pour le 
surpoids et l'obésité chez les enfants traités et guéris d'une leucémie aiguë en Suisse 
romande et de comparer ces résultats à ceux d'études internationales. Pour répondre à 
ces questions nous avons inclus 54 patients (40 de Lausanne et 14 de Genève) traités 
pour une leucémie aiguë. Seuls les enfants à 5 ans de leur première rémission clinique, 
sans atteinte du système nerveux central, testiculaire ou médullaire et traités par 
chimiothérapie seule sont retenus. Leur poids, taille sont enregistrés durant les phases 
précises de traitement (au diagnostic, à la rémission, fin de consolidation, milieu-
maintenance et en fin de traitement) puis annuellement jusqu'à 12 ans post fin de 
traitement. Le BMI (kg/m2) et sa déviation standard BMI-SDS (spécifique pour l'age et 
le sexe) pour les patients et leurs parents sont calculés selon les valeurs internationales 
(IOTF) respectivement BMI-SDS >1.645 (p<0.05) pour le surpoids et> 1.96 (p<0.025) 
pour l'obésité. 
Les résultats de ce travail confirment une prévalence double de surpoids (30% versus 
17%) et quadruple d'obésité (18% versus 4%) au sein de la population d'enfants traités 
pour une leucémie aiguë comparées à la population suisse standard. Les facteurs de 
risque impliqués sont le BMI initial au diagnostic et le BMI maternel contrairement à 
l'age, sexe, stéroïdes et au BMI paternel. 
Ces données confirment une prévalence significative d'enfants en surpoids/obèses au 
sein de cette population avec des résultats similaires à ceux retrouvés dans des études 
internationales récentes. Les facteurs de risque identifiés semblent plutôt liés à 
l'environnement familial qu'aux traitements. Ces constatations pourraient être le 
résultat d'interactions complexes entre "le background génétique", les facteurs 
environnementaux, les habitudes socioculturelles (activité physique, status nutritionnel) 
paramètres non évalués dans cette revue. Des études plus larges, prospectives sont 
nécessaires pour clarifier les rôles des différents facteurs de risque et de leurs 
interactions ; celles-ci devraient inclure des données génétiques (LEPR), taux de leptine, 
activité physique et le status nutritionnel. Enfin, l'identification des patients à risque est 
cruciale afin de prévenir les effets secondaires cardio-vasculaires, métaboliques bien 
connus liés au surpoids et à l'obésité. 
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Background. Childhood acute lymphoblastic leukemia (ALL) 
with current cure rates reaching 80% emphasizes the necessity to 
determine treatment related long-term effects. The present study 
examines the prevalence of and the risk factors for overweight and 
obesity in a cohort of ALL survivors treated and living in the French 
speaking part of Switzerland. Methods. ln this retrospective two-
center study, height and weight of 54 patients diagnosed with ALL in 
first complete remission and treated with chemotherapy only were 
recorded al specified time points during treatment and off-therapy. 
Body mass index (BMI) and its age- and gender-adjusted standard 
deviation score (BMl-SDS) were calculated for the patients and their 
parents separately. Overweight and obesity were defined by a 
threshold of BMl-SDS > 1.645 and BMl-SDS > 1.96, respectively. 
Results. At last follow-up, 16 (30%) of the 54 survivors were 
overweight and 10 (18%) were obese. The off-treatment period was 
most al risk with 11 of the 16 becoming overweight and 9 of the 10 
becoming obese du ring that period. Overweight/obesity at diagnosis 
and abnormal maternai BMI were significantly associated with 
abnormal weight al follow-up, while age at diagnosis, gender, 
cumulative dose of steroids and paternal BMI showed no association. 
Conclusions. Consistent with published evidence from other regions 
of the developed and developing world, there is a significant 
prevalence of obesity in young ALL survivors in the French speaking 
part of Switzerland. Factors significantly associated with this late 
effect were mostly related to the familial background rather than to 
the treatment components. Pediatr Blood Cancer 
© 2008 Wiley-Liss, lnc. 
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INTRODUCTION 
Treatment of childhood acute lymphoblastic leukemia (ALL) is 
one of the success stories of modern medicine with current cure rates 
reaching 80% [l]. With the growing number of survivors, it becomes 
increasingly important to understand treatment-related long-term 
effects. In North America, Western Europe, Australia, New 
Zealand, some parts of the Middle East and in rapidly developing 
countries such as China, overweight and obesity are now more 
important forms of malnutrition than undernutrition in the general 
pediatric population [2,3]. Zee and Chen [4] provided the first report 
of a potential association between obesity and ALL therapy in 1986. 
Since then other studies [5-11] showed an association between 
patients undergoing ALL therapy and excessive weight gain. 
Nevertheless, the etiologic rotes of some patient characteristics 
(e.g., age, gender and body mass index (BMI kg/m2) at diagnosis) 
and of different treatment components (e.g., the dose of cranial 
radiotherapy (CRT), the type of steroids and the cumulative dose of 
steroids) in the development of overweight/obesity remain unclear 
[8,9]. Furthermore, recent studies [10,11] point out a strong 
correlation between some of the patient's familial characteristics 
and the risk of long-term excessive weight gain in this cohort. 
The objective of this retrospective study was to assess the 
prevalence of, and the risk factors for overweight and obesity in a 
representative cohort of ALL survivors treated and living in the 
French speaking part of Switzerland. Height and weight measure-
ments were done at specified time points during treatment and 
follow-up periods in order to determine the most sensitive period for 
ab normal weight gain. Severa! potential risk factors were examined, 
including the cumulative steroid doses and both the parental and 
persona! growth parameters. 
METHODS 
Patients were drawn from a previously identified group of 60 
children diagnosed with precursor B-cell ALL in the French 
speaking part of Switzerland (Geneva and Lausanne) between 1990 
and 2000 [12]. Only patients without initial central nervous system 
or testicular involvement, treated without CRTand in first complete 
remission from at least 5 years after diagnosis were included. 
© 2008 Wiley-Liss, Inc. 
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Patients with trisomy 21, Prader-Willi or Beckwith-Wiedemann 
syndromes were excluded from the study. The study protocol was 
reviewed and approved by the respective Institutional Review 
Boards. From the initial 60 eligible patients, 4 were excluded 
because they were lost during the follow-up period and 2 were 
excluded because of central nervous system relapse. Of the 
remaining 54 patients, 40 were from Lausanne and 14 from Geneva. 
Patient's ages at diagnosis of ALL ranged from 2 to 12 years, with a 
median of 3.5 years. 
ALL treatment was administered according to a series of 
subsequent protocols from the Paediatric Oncology Group (POG): 
POG 8602, POG 9201, POG 9005106, POG 9405/06, POG 9605, 
and POG 9904105106. Treatment details have been published 
elsewhere [13]. Briefty, ail protocols included a 4 weeks induction 
with prednisone (40 mg/m2/day) or dexamethasone (6 mg/m2/day) 
as well as 5-7 days blocks of steroids at different time points during 
consolidation, intensive continuation or maintenance. Patients were 
followed annually up to 12 years after completion of therapy, with a 
median follow-up of 6 years. In order to determine a critical period 
for excessive weight gain, height and weight were recorded and BMI 
and its standard deviation score (defined as BMI-SDS) computed at 
specific and specified time points: diagnosis, complete remission, 
end of consolidation, mid-maintenance, end of treatment and 
annually during follow-up. Patient's heights and weight were 
retrospectively extracted from the medical charts. Both BMI and 
BMI-SDS were computed and scored according to the International 
Obesity Task Force (IOTF) criteria [14,15] overweight being 
defined by a gender- and age-specific BMI-SDS > 1.645 (exceeding 
95th percentile) and obesity by a gender- and age-specific BMI-
SDS > 1.96 (>P97.5). In addition, the BMI and BMI-SDS of the 
parents were calculated from self-reported data. Parents were 
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Fig. 1. Overweight and obesity in ALL survivors compared to the general pediatric Swiss population. [Col or figure can be viewed in the online 
issue, which is available at www.interscience.wiley.com.] 
considered either normal (BMI < 25 kg/m2), overweight (BMI 25-
30 kg/m2) or obese (BMI > 30 kg/m2). 
For statistical analysis, data on patient outcomes were locked on 
May 31, 2005. To assess and compare the overweight and obesity 
rates in the different groups, cumulative incidences and their 95% 
confidence intervals (95% Cl) were calculated comparably to the 
Kaplan-Meier method. Univariate analysis of the influence of 
different variables on overweight and obesity was performed 
applying the log-rank-test. Continuously measured potentially 
influencing variables were dichotomized or categorized according 
to quartiles, where applicable. Two-sided tests were used through-
out, and P-values below 0.05 were considered significant. No 
correction for the multiple comparisons performed in this 
exploratory study was applied. S-PLUS 6.0 (Insightful Corp., 
Seattle, WA) software was used. 
RESULTS 
At last follow-up, nearly half of the ALL survivors had excessive 
weight: 16 (30%) of the 54 patients were overweight and IO (18%) 
obese. These numbers contrast with the rates observed in the general 
Swiss population of comparable age and gender, 17% and 4%, 
respectively (Fig. 1) [19]. Considering the entire observation period 
from the diagnosis until the last contrai, a total of 32 patients (59%) 
exceeded at least once the overweight (N = 18, 33%) or the obesity 
(N = 14, 26%) threshold. 
The majority of the overweight survivors (11of16) and nearly al! 
obese survivors (9 of 10) developed excessive weight gain du ring the 
follow-up period. During therapy, 17% of the patients (9/54) became 
overweight. At the end of consolidation 13% of the patients (7/54) 
became obese as a result of the steroids. This abnormal weight gain 
resolved spontaneously later on in the course of treatment in most 
cases (Fig. 2). There was no effect of the cumulative dose of steroids 
on the incidence of overweight or obesity in the survivors at follow-
up (Fig. 3). 
Two risk factors were associated with the development of 
ab normal weight gain in a statistically significant way. The first was 
an abnormal BMI-SDS atdiagnosis of ALL. White only 14 (30%) of 
the 47 survivors having a normal BMI-SDS became obese in the 
long term, 5 of the 7 initially overweight or obese chitdren reached 
the obesity threshold during the follow-up period (P < 0.004; 
Fig. 4). The second was maternai BMI. White only 5 (20%) of the 24 
chitdren with normally weighting mothers became overweight or 
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obese, 4 of the 5 with overweight or obese mothers were fulfilling 
the obesity threshold (P = 0.021; Fig. 5). Paternal BMI was not 
significantly associated with the patient's risk for overweight at 
follow-up: 7 (33%) of the 21 chitdren with normal weighting 
fathers, compared to 5 of the 7 wi th overweight orobese fa th ers were 
overweight or obese at follow-up (P = 0.077). Gender and age at 
diagnosis had no significant association with the development of 
overweight or obesity (data not shown). 
DISCUSSION 
As in other countries, we found a high prevalence of overweight 
and obesity in our population of ALL survivors with almost double 
and fourfold rates compared to the standard Swiss chitdren of 
similar age and sex, respectively. These results are comparable with 
the one from international studies [6,7,8,16-18] but the treatment 
exposure consisted mostly of chemotherapy and CRT. Oeffinger 
et al. [6], in a recent Childhood Cancer Survivor Study (CCSS) 
reported on 1,765 survivors of chitdhood ALL and a comparison 
group of 2,565 siblings. They found respectively a prevalence of 
28% and 17% of overweight and obese patients. Kourti et al. [18] 
studied the frequency of overweight and obesity in a cohort of 52 
survivors of ALL. They concluded that 48% were overweight and 
8% were obese. Sklar et al. [8] reported on a prevalence of 30% of 
obese patients in their cohort of 126 survivors of childhood ALL, 
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Fig. 2. Number of survivors with abnormal BMI-SDS during the 
observation period. [Color figure can be viewed in the online issue, 
which is available at www.interscience.wiley.com.] 
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Fig. 3. Effect of cumulative steroid dose: P > 0.050. 
knowing that most of them were undergoing cranial radiotherapy 
and chemotherapy (88/126). 
Different hypotheses can be discussed to explain these findings. 
Abnormal weight gain could be the result of the drugs used to treat 
ALL, especially steroids, which are known to increase body fat. 
Although we observed the expected excessive weight gain after 
induction/consolidation, the majority of patients returned to a 
normal weight and BMI later in the course of therapy, a finding 
clearly speaking against a long-lasting effect of the steroids. 
Interestingly, the majority of our patients being overweight or obese 
at follow-up developed their abnormal weight gain after the end of 
therapy, another argument against directly steroid-related effects. 
Cranial irradiation has been clearly linked to a series oflate events in 
ALL survivors, including overweight and obesity. Former late 
effects studies in ALL survivors demonstrated that CRTwas a major 
risk factor for overweight/obesity in the long-term and discussed 
several hypotheses and mechanisms [8,9] Brennan et al. [9] 
suggested that radiation damage to hypothalamic neurons control-
ling eating behaviors and leptin resistance were mainly involved in 
the development of late excessive weight gain in this population. 
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However, due to small sample sizes and Jack of optimal comparison 
groups, these hypotheses remain extremely speculative and need 
larger prospective cohorts to be confirmed. 
If not, or not only therapy related, overweight and obesity in 
long-tenn ALL survivors could be associated with the genetical, or 
more broadly speaking the familial background of the patients. We 
looked therefore at patient's own BMI at ALL diagnosis and 
parental BMI as possible relevant markers for this background. 
Although based on a relatively small patients and parents 
population, our findings point to a statistically significant and 
clinically relevant impact of the patient's own body constitution 
represented by his/her BMI at ALL diagnosis and the maternai BMI; 
paternal BMI showed a tendency for association. "Familial" is of 
course broader than "genetical" and includes potential interactions 
between an individual genetical condition and the family's 
environment, that is, type of diet, physical activity a.o. Furthermore, 
this "familial background" will be able to internet with the different 
components of a given therapy. Recent studies [10, 11] explored 
those interactions: Shaw et al. found a significant maternai 
predisposition where 59% of their obese female survivors had 
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Fig. 5. Overweight, effect of maternai obesity. 
obese mothers while only 14% of them had obese fathers. Ross et al. 
reported a high correlation between the LEPR (leptin receptor gene) 
polymorphism and obesity in female ALL survivors being 
homozygous for the Arg genotype and having undergone CRT. 
Comparably to our study, Shaw et al. [11] pointed out the role of 
maternai BMI as risk factor for obesity in ALL survivors: a larger 
percentage of female subjects whose mothers were obese became 
obese themselves, but only if treated with CRT. A retrospective 
study conducted by Razzouk et al. [21] concluded that patients 
fulfilling the overweight or obese threshold at diagnosis were the 
most at risk of becoming obese when reaching adult height. These 
results are of particular interest because there were no significant 
differences in the BMI rates between patients having undergone 
CRT and those who received chemotherapy only. This study also 
showed that the familial weight pattern has a deeper impact on the 
survivors BMI than treatment components as CRT. These data 
highlight the need to further investigate the complex interactions 
between genetic background, environmental factors and treatment 
components. 
There are some caveats in interpreting the results of the current 
study. First, the small number of ALL survivors included as well as 
the retrospective study design could be responsible for the Jack of 
statistical significance of certain risk factors, for example, the 
impact of the cumulative steroid dose. Second, the BMI of the 
mothers and fathers have been computed from self-reported heights 
and weights, which are both subject to a degree of imprecision. 
Furthermore, it could be argued that BMI and BMI-SDS are not the 
best means for estimating overweight and obesity, because they do 
not distinguish fat mass from Jean mass. More precise methods like 
dual X-ray absorptiometry should be used to overcome this 
difficulty, but they are both time-consuming and expensive. 
Therefore, BMI remains the standard measure of obesity in the 
majority of population based studies. A third caveat is the BMI-SDS 
reference values used as eut-offs for overweight and obesity in 
children. Two options are cmTently available, from the US Centre 
for Disease Contrai and Prevention (CDC) and from the IOTF. The 
overall performance of the CDC reference values is superior. 
Nevertheless we calculated the z-scores in the present study 
according to the normative data from IOTF (Cole et al.), since 
international studies typically use the IOTF criteria and we wished 
to make comparisons with these studies. Fourth and finally, data on 
genetic [20,22] and anthropometric data, detailed information on 
Pediatr Blood Cancer DO! 10.1002/pbc 
ethnicity, nutritional habits and physical activity were not available 
in the present study. Our findings are nevertheless important because 
they confirm the high prevalence of overweight and obesity even in a 
homogenous group of survivors of childhood B-precursor ALL 
treated with chemotherapy only. By computing BMI-SDS at very 
specific lime-points during and off therapy we found that the 
majority of patients developed excessive weight gain during the 
follow-up period. 
Increased rates of obesity in this population may be the result of 
complex interactions between specific genetic backgrounds, as 
indicated by patient and maternai baseline BMls, as well as 
environmental factors, such as specific treatment components or 
socio-cultural habits (physical activity, nutritional status) not tested 
in the present study. Larger prospective cohort studies are needed to 
clarify the individual roles and interactions ofthese risk factors in a 
given patient. Specifically future studies should include data on 
LEPR and other gene polymorphisms, levels of leptin, physical 
activity, dietary habits, nutritional status, as well as BMis of the 
survivors, parents and siblings. Earl y detection of patients atrisk and 
early implementation of preventive interventions (enhancement 
of physical activity, appropriate diet, etc.) are important for the 
effective prevention of obesity which, in turn, may reduce the risk of 
the metabolic syndrome and its long-term deleterious cardiovas-
cular consequences. 
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